Arcutis Biotherapeutics, Inc. (ARQT) [Rocket]

Overview

Arcutis Biotherapeutics, Inc. (ARQT)

Add to portfolio

1m \| 3m \| 6m \| 1y \| 2y \| 5y \| 10y

Recent News + Filings (All items)

Date Filed	Type	Description
10/03/2023	4	Edwards Larry Todd (Chief Commercial Officer) has filed a Form 4 on Arcutis Biotherapeutics, Inc.
10/03/2023	3	Edwards Larry Todd (Chief Commercial Officer) has filed a Form 3 on Arcutis Biotherapeutics, Inc.
09/27/2023	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
08/22/2023	4	Burnett Patrick (See Remarks) has filed a Form 4 on Arcutis Biotherapeutics, Inc.
08/21/2023	144	Form 144 - Report of proposed sale of securities:
08/18/2023	8-K	Quarterly results
08/15/2023	144	Form 144 - Report of proposed sale of securities:

Revenue Mix by Segment

Financial Summary (All financials)

In millions, except per share items	Dec-31-22	Dec-31-21	Dec-31-20	Dec-31-19	Dec-05-19	Dec-31-18	Dec-05-18	Dec-31-17
Revenues	3.7	0.0	0.0	0.0	36.5	0.0	17.9	3.4
Revenue growth					103.6%	-100.0%	425.9%
Cost of goods sold	0.8	0.0	0.0	0.0	43.1	0.0	19.7	6.8
Gross profit	2.9	0.0	0.0	0.0	-6.6	0.0	-1.8	-3.4
Gross margin	79.5%				-18.1%		-10.0%	-100.0%
Research and development	182.4	145.6	115.3	36.5		17.9
General and administrative	122.1	61.0	21.3	6.6	6.6	1.8	1.8	0.7
EBITA	-301.3	-206.5	-136.6	-43.1	-43.1	-19.7	-19.7	-4.1
EBITA margin	-8174.6%				-118.1%		-110.0%	-120.4%
Amortization of intangibles	0.3
EBIT	-301.6	-206.5	-136.6	-43.1	-43.1	-19.7	-19.7	-4.1
EBIT margin	-8183.0%				-118.1%		-110.0%	-120.4%
Pre-tax income	-311.5	-206.4	-135.7	-42.0	-42.0	-19.3	-19.3	-5.0
Income taxes	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Tax rate	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Net income	-311.5	-206.4	-135.7	-42.0	-42.0	-19.3	-19.3	-5.0
Net margin	-8449.8%				-115.0%		-107.3%	-145.9%

Diluted EPS	($5.66)	($4.18)	($3.80)	($22.78)	($22.78)	($15.53)	($15.53)	($7.16)
Shares outstanding (diluted)	55.0	49.4	35.7	1.8	1.8	1.2	1.2	0.7

EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.